← Back
ADARx Pharmaceuticals
ADRX · listed on Nasdaq · worth $1.99 billion
$17.95
−0.99% on Oct 28
Eleven insider buys in the last year, $67.6 million in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
49.4M shares
45% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, five insiders bought ADARx Pharmaceuticals stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
SR One Capital Management
Bought $10.07M on Sep 28 — 592,593 shares at $17.00, held through a trust or family, 11% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
10% owner
Simeon George
Bought $10.07M on Sep 28 — 592,593 shares at $17.00, held through a trust or family, 11% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
10% owner
Carl L. Gordon
Bought $10M on Sep 28 — 588,235 shares at $17.00, held through a trust or family, 100% of what they now own.
No earlier purchases to measure
Big investors
People and funds that reported owning 5% or more of ADARx Pharmaceuticals, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.LAV Biosciences Fund V10.5%Oct 16
Filed by someone who owns 5% or more and may try to influence how the company is run.SR One Capital Management9.3%Oct 5
Filed by someone who owns 5% or more and may try to influence how the company is run.Orbimed Advisors LLC14.0%Oct 2
Filed by someone who owns 5% or more and does not plan to influence the company.BCLS Fund III Investments6.3%Oct 1
All reports
Every insider trade and SEC report we hold for ADARx Pharmaceuticals.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 30BoughtErez ChimovitsSep 30 · Traded Sep 28 · Director+0.7%via a trust or family61,516 @ $17.00$1.05M
Sep 30BoughtCarl L. GordonSep 30 · Traded Sep 28 · 10% owner+100%via a trust or family588,235 @ $17.00$10M
Sep 30BoughtCarl L. GordonSep 30 · Traded Sep 28 · 10% owner+0.7%via a trust or family61,516 @ $17.00$1.05M
Sep 30BoughtCarl L. GordonSep 30 · Traded Sep 28 · 10% owner+2.1%via a trust or family300,249 @ $17.00$5.1M
Sep 30BoughtOrbimed Advisors LLCSep 30 · Traded Sep 28 · 10% owner+100%via a trust or family588,235 @ $17.00$10M
6 more with Pro →Analysts, earnings and news
Analysts' price target
$34.25 average
4 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.